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Abstract
Our studies of renal phosphoinositide levels and metabolism in the pcy mouse with polycystic kidney disease (PKD) suggest that
phosphatidylinositol kinase (PtdInsK) and phospholipase C (PLC) are elevated in this renal disorder. Therefore, the steady-state levels of
select isoforms of these enzymes were examined in renal cytosolic and particulate (detergent-soluble) fractions in male and female normal
and CD1-pcy/pcy (pcy) mice at 60, 120 and 180 days of age, and in male and female normal and diseased (Han:SPRD-cy) rats at 28 and 70
days of age. Disease-related increases in phosphatidylinositol 4-kinaseh (PtdIns4Kh) and PLCg1 levels were present in both models.
PtdIns4Kh levels were higher by as much as 233% in pcy mice and by 95% in diseased Han:SPRD-cy rats compared to normals of the same
age and gender. Steady-state levels of PLCg1 were as much as 74% and 35% higher in pcy mice and diseased Han:SPRD-cy rats, respectively,
compared to their controls. The consistency of these alterations in two accepted models of PKD indicates the importance of the
phosphoinositide signalling pathway in the evolution of this disorder, and represents a potential site for therapeutic intervention. D 2002
Elsevier Science B.V. All rights reserved.
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1. Introduction
Polycystic kidney disease (PKD) encompasses a variety
of kidney cystic disorders that are characterized by abnor-
mal renal cyst growth and development. The autosomal
dominant form is a hereditary disorder that affects approx-
imately 1 in 1000 people, and causes renal death at an
average age of 50–55 years [1]. Polycystic kidneys contain
hundreds of fluid filled cysts which cause increased renal
size in humans and ultimately renal failure.
While the presence of PKD is genetically determined, the
rate of disease progression is significantly influenced by
mediators of the cell environment, such as growth factors
and dietary factors [2]. Growth factor abnormalities include
epidermal growth factor (EGF), transforming growth factor-
a and -h (TGFa and TGFh), hepatocyte growth factor and
insulin-like growth factor-I (IGF-I). Activation of the recep-
tors for many of the growth factors that are altered in PKD
results in autophosphorylation at tyrosine residues and phos-
phorylation of other substrates, including SH2-containing
proteins.
In relation to this, we demonstrated that phosphoinositide
metabolism, which is regulated in part by tyrosine phos-
phorylation, is altered in the pcy model of PKD [3–6].
Using the DBA-pcy/pcy mouse, mass analysis revealed that
the level of phosphatidylinositol (PtdIns) is considerably
lower in pcy mouse kidneys, while the level of PtdIns-
phosphate (PtdInsP) is not different [3,6]. As a result, the
PtdInsP/PtdIns ratio is higher in pcy mouse kidneys. In a
tracer isotope study [4], pcy and normal mice were injected
intraperitoneally with [3H]inositol and sacrificed 12 min
later, so that the radioactivity in the phosphoinositides pre-
dominantly reflects synthesis. The [3H]PtdInsP/[3H]PtdIns
ratio also was elevated in this study, suggesting that the
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conversion of PtdIns to PtdInsP was elevated in pcy mouse
kidneys.
In addition, both mass and radiolabelled PtdIns-4,5-
bisphosphate (PtdIns-4,5-P2) as well as the PtdIns-4,5-P2/
PtdInsP ratio are lower in pcy mouse kidneys compared to
normals [4]. This lower level of renal PtdIns-4,5-P2 in pcy
compared to normal mice could be due to decreased syn-
thesis or increased degradation of this phosphoinositide. Our
mass and labelling studies indicate that synthesis of PtdIns-
4,5-P2 (via PtdInsP 5-kinase activity) is not different in pcy
compared to normal mouse kidneys, but that degradation of
this phosphoinositide may be elevated in the diseased
kidneys. In addition, renal diacylglycerol levels are elevated
in pcy mice [5], consistent with increased level and/or
activity of a phosphoinositide-specific phospholipase C
(PLC) in pcy mouse kidneys compared with normals.
Since several growth factors are altered in PKD, specific
isoforms of PLC and PtdIns kinase (PtdInsK) that are
activated by tyrosine phosphorylation following growth
factor receptor activation [7–11], were examined by immu-
noblot analysis. To test our hypothesis that the levels of
phosphatidylinositol 3-kinase (PtdIns3K), PtdIns4Kh and
PLCg1 were higher in PKD kidneys, we first used the CD1-
pcy/pcy (pcy) mouse model of PKD in which the decline in
renal function begins in adulthood. We confirmed that these
findings are not an anomaly of this model by using another
model of PKD in which the decline in renal function occurs
during the growth phase, namely the Han:SPRD-cy rat.
2. Methods
2.1. Animals
The CD1-pcy/pcy (pcy) mouse and the Han:SPRD-cy rat
used in this study are well-characterized and accepted
models of autosomal dominant PKD [12,13]. The animal
experimental protocol was in accordance with the National
Research Council’s Guide for the Care and Use of Labo-
ratory Animals and was approved by the University Animal
Care and Use Committees. Animals were from our colonies,
which were established from breeding stock obtained from
V.H. Gattone II (pcy mice) and B.D. Cowley (Han:SPRD-cy
rats), University of Kansas Medical Centre. All animals were
housed in temperature- (22 to 24 jC), humidity- (50% to
60% relative humidity) and light- (12-h light/dark cycle)
controlled conditions. Animals were weaned between 3 and
4 weeks of age and received standard lab chow and tap water,
which were provided ad libitum. Normal and diseased mice
(n = 5–6) were killed at 60, 120 or 180 days and normal and
diseased rats (n = 6–10) were killed at 28 or 70 days. For the
mice, cyst development is slow and decline in markers of
renal function does not usually occur until after 6 months of
age [13,14]. In contrast, cyst growth is rapid in the rat and
markers of renal function are significantly altered by 70 days
of age [12,15]. Animals were lightly anesthetized with CO2
before decapitation and tissues were removed, weighed and
immediately frozen in liquid nitrogen.
2.2. Sample preparation
Tissues were lyophilized and a representative sample was
homogenized in 100 volumes of ice-cold homogenization
buffer [50 mM Tris–HCl [pH 7.4], 250 mM sucrose, 2 mM
EDTA, 1 mM EGTA, 10 mM h-mercaptoethanol, 100 AM
sodium orthovanadate, 1 Ag/ml soybean trypsin inhibitor,
144 AM 4-(2-aminoethyl) benzene-sulfonyl fluoride, and 25
Ag/ml of aprotinin, pepstatin and leupeptin (all reagents
from Sigma, St. Louis, MO)] [16]. Homogenates were
centrifuged at 100,000 g for 30 min at 4 jC and the
supernatant, which represents the cytosolic fraction, was
collected. The remaining pellet was resuspended in 15
Fig. 1. Steady state levels of PtdIns4Kh in normal and pcy mouse kidney cytosolic fractions. *P < 0.05, significantly different from same gender and age
normals.
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volumes of the homogenization buffer containing 1% Triton
X-100 (Sigma), incubated on ice for 10 min and centrifuged
at 100,000 g for 30 min at 4 jC. The resulting supernatant
was collected as the particulate extract and represents the
Triton-soluble fractions of the plasma and intracellular
membranes. Homogenates were stored at  80 jC until
analyses. Protein concentrations of all fractions were deter-
mined by protein assay as described by Bradford [17], with
bovine serum albumin as the standard.
2.3. Immunoblotting
Samples were prepared for immunoblotting using
Laemmli sample buffer [18], and electrophoresed for 2 h
at 200 V on 7.5% SDS-PAGE minigels with 4% stacking
gels. Following electrophoretic protein separation, the gels
were soaked in transfer buffer for 10 min and the proteins
were transferred onto PVDF membranes at 375 mA for a
minimum of 2 h. After removal from the transfer apparatus,
the membranes were blocked with 5% skim milk or goat
serum (Jackson ImmunoResearch Laboratories Inc., USA)
in Tris-buffered saline with 0.1% Tween. Primary antibodies
to PtdIns3K, PtdIns4Kh and PLCg1 (catalogue numbers 06-
195, 06-578 and 06152, respectively) were obtained from
Upstate Biotechnology (USA). Incubation time was at least
12 h at 4 jC. For mouse tissues, antibody titres for
PtdIns3K, PtdIns4Kh and PLCg1 were 1:2000, 1:10,000
and 1:500, respectively. For rat kidneys, dilutions of 1:2000
were used for PtdIns4Kh and PLCg1.
For the mouse tissues, all secondary antibody incubations
were 2 h at room temperature in a 1:10,000 dilution of an
alkaline phosphatase-conjugated goat anti-rabbit IgG (Jack-
son ImmunoResearch Laboratories). Bands were visualized
by developing the membranes with NBT/BCIP (Gibco
BRL). The MCID system (Imaging Research, St. Cathar-
ines, ONT, Canada) was employed to determine the optical
densities of the bands of interest. For the rat tissues, a
peroxidase-conjugated secondary antibody was incubated
for 1 h at room temperature at a dilution of 1:50,000. Mem-
branes were then incubated with Chemi Glowk (Alpha
Innotech, San Leandro, CA) and image analysis and quan-
titation of immunoreactive bands was performed using the
Fluorchem Imager (Alpha Innotech).
A range of protein amounts was loaded onto gels for each
antibody to ensure that the quantitative comparisons could
be made for results within each isoform. The amount of
protein that was in the middle of the linear response and
used for analyses of the enzymes of interest ranged from 1 to
14 Ag of protein. Colour molecular weight markers, Jurkat
cell lysates and bovine brain cytosol were used as standards
to verify the identity of the bands of interest. Negative
controls included using a nonspecific antibody (anti-oval-
bumin) or omitting the primary or secondary antibody.
2.4. Statistical analyses
All samples from one age and gender group were loaded
on the same gel with the same amount of protein and were
Fig. 2. Steady state levels of PtdIns4Kh in normal and pcy mouse kidney particulate fractions. *P < 0.05, **P < 0.01, significantly different from same gender
and age normals.
Table 1
Steady-state levels (O.D./mg protein) of PtdIns4Kh and PLCg1 in livers of
pcy mice
Age (days) Gender PtdIns4Kh PLCg1
Cytosolic Particulate Cytosolic Particulate
60 male 117F 11 120F 33 67F 13 90F 16
120 male 108F 5 107F 12 86F 14 84F 6
180 male 126F 11 83F 13 85F 5 77F 11
60 female 111F11 79F 19 68F 14 98F 13
120 female 89F 13 116F 27 103F 8 142F 25
180 female 88F 5 70F 8* 80F 3* 63F 9*
Data are mean optical densityF S.E., expressed relative to normal controls
of the same age and gender. PtdIns4Kh, phosphatidylinositol 4-kinaseh;
PLCg1, phospholipase PLCg1.
* P< 0.05, compared to normal control of same age and gender.
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analyzed together. Data was analyzed by Student’s t-test
when the data displayed homogeneity of variance. If var-
iances were not equal, as detected by either Levene’s or
Bartlett’s test, significant differences were determined using
Wilcoxon’s test. Data are expressed as meanF S.E. for the
normal and diseased groups, with the mean of the normal
controls equated to 100 and the other values expressed
relative to the normal group.
3. Results
3.1. PtdInsK levels
Immunoblot analysis demonstrated the presence of
PtdIns4Kh in the kidneys and livers of pcy and control
mice in both the cytosolic and particulate fractions. In the
kidneys of 180-day-old pcy mice compared to normals, the
level of PtdIns4Kh in the cytosolic and particulate fractions
was elevated in both males (by 53% and 233%, respec-
tively) and females (by 80% and 115%, respectively) (Figs.
1 and 2). In females, the steady-state levels of PtdIns4Kh
were higher by approximately 48% in the particulate frac-
tion of 60-day-old mice, and by 80% in both fractions at 120
days of age. In contrast to the diseased kidneys, the levels of
PtdIns4Kh in livers from pcy mice with PKD were not
elevated compared to controls, with the only difference
being a 30% lower level of PtdIns4Kh in the particulate
fraction of livers from 180-day-old female pcy mice com-
pared to controls (Table 1).
To determine whether the renal alterations were present
in another animal model of PKD, the kidneys of Han:SPRD-
cy rats were analyzed for PtdIns4Kh. In both models, the
progression of cyst growth in PKD is reflected in changes in
Fig. 3. Steady state levels of PtdIns4Kh in normal and polycystic Han:SPRD-cy rat kidney particulate fractions. **P < 0.01, significantly different from same
gender and age normals.
Fig. 4. Steady state levels of PLCg1 in normal and pcy mouse kidney cytosolic fractions. *P< 0.05, significantly different from same gender and age normals.
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renal size in diseased animals compared to normals. In 180-
day-old mice, kidney weight relative to body weight (g/100
g) in pcy compared to normal animals was 1.60F 0.12 vs.
0.79F 0.08 ( P < 0.001) in males and 1.90F 0.22 vs.
0.58F 0.03 (P < 0.001) in females. A more than doubling
of kidney weight also occurred by 70 days in male
Han:SPRD-cy rats with relative kidney weights of 1.06F
0.07 vs. 0.44F 0.01 (P < 0.001) in diseased compared to
normal animals. In contrast, the disease is less aggressive
in female rats, with relative kidney weights of 0.58F 0.02
vs. 0.38F 0.01 (P < 0.001) in diseased compared to nor-
mal animals. Significant differences in PtdIns4Kh levels
were observed in only the particulate fraction from renal
extracts of 70-day-old male Han:SPRD-cy rats, where
PtdIns4Kh levels were 95% higher in diseased compared
to normal rats (Fig. 3).
Our previous data using in vivo labelling of phosphoi-
nositides in pcy mice demonstrated that more than 98% of
the PtdInsP activity was associated with the PtdIns-4-P
isomer, but that small amounts of PtdIns-3-P also were
present. Immunoblot analyses of pcy mouse kidneys and
livers, however, indicate that the levels of PtdIns3K are not
altered (data not shown).
3.2. PLCg1 levels
The pattern of PLCg1 expression in the kidneys and
livers of pcy mice was similar to that of PtdIns4Kh. In
180-day-old pcy mice compared to normals, renal levels of
PLCg1 were higher in cytosolic and particulate fractions in
both male (by 61% and 48%, respectively) and female (by
74% and 64%, respectively) animals (Figs. 4 and 5). In 60-
Fig. 5. Steady state levels of PLCg1 in normal and pcy mouse kidney particulate fractions. *P < 0.05, **P < 0.01, significantly different from same gender and
age normals.
Fig. 6. Steady state levels of PLCg1 in normal and polycystic Han:SPRD-cy rat kidney cytosolic fractions. *P < 0.05, ***P< 0.001, significantly different
from same gender and age normals.
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and 120-day-old pcy females, PLCg1 was 41% and 67%
higher, respectively, in the particulate fractions of the
kidneys. PLCg1 levels were not elevated in the livers of
pcy mice, with the only significant differences being in the
cytosolic and particulate fractions of livers from 180-day-
old female animals (20% and 37% lower, respectively)
(Table 1). In the Han:SPRD-cy rats, PLCg1 levels were
elevated in the cytosolic fractions of kidneys from 70-day-
old males (by 35%) and females (by 12%) (Fig. 6). PLCg1
levels in particulate fractions did not appear to differ
between extracts from normal and diseased kidneys. How-
ever, the low levels present precluded accurate quantifica-
tion of these bands.
4. Discussion
The current study demonstrates that the levels of specific
enzymes PtdIns4Kh and PLCg1 are elevated not only in pcy
mouse kidneys, but also in the polycystic kidneys of another
accepted animal model of PKD, namely the Han:SPRD-cy
rat. This is consistent with our previous reports on phos-
phoinositide metabolism in the pcy mouse in which mass
quantitation and tracer radioisotope analyses suggested that
the activity of renal PtdInsKs and PLC are elevated in this
model of PKD [3–6].
Both PtdIns4Kh and PLCg1 are downstream of growth
factor receptors that are activated via tyrosine phosphory-
lation events [8,10,19–21]. The level of several growth
factors and their receptors are known to be upregulated in
PKD and in animal models of this disease. EGF concen-
trations are altered in PKD [22–25], and hyperresponsive-
ness to EGF has been demonstrated in cultured cells
derived from PKD cystic epithelium [25]. The distribution
and metabolism of EGF is abnormal in several mouse
models of PKD [24,26–28], and the EGF receptor is
mislocated to the apical membrane of renal epithelial cells
derived from mice with PKD and from PKD patients [1].
EGF and IGF-I also are found in renal cyst fluid [27,29,30].
Both EGF receptor and TGFa are overexpressed in human
PKD [31]. The expression of the TGFa transgene in the
kidney results in the formation of renal cysts in otherwise
normal mice and in the acceleration of cyst enlargement in
pcy mice with PKD [26,32]. TGFa is a close relative of
EGF, and like EGF, exerts its effect on cells through bin-
ding to the EGF receptor. In addition to EGF, gene expres-
sion of IGF-I, platelet-derived growth factor and fibroblast
growth factor also is affected in the pcy animal model of
PKD [28]. In the Han:SPRD-cy rat, serum and kidney le-
vels of IGF-I are elevated in diseased animals compared to
normals [15].
Increased tyrosine kinase activity of the EGF receptor in
cystic renal tissue is a functional event that is part of the
disease pathway of renal cyst formation. This has been
demonstrated in an in vitro model of tubular cyst develop-
ment in which inhibition of tyrosine kinase activity resulted
in a reduction in tubular epithelial cell hyperplasia [33].
Furthermore, in vivo inhibition of the EGF receptor or
inhibiting EGF tyrosine kinase activity in an animal model
of PKD slows disease progression [34–36], indicating the
importance of tyrosine kinase-mediated events in PKD.
EGF stimulates the activity of PLCg1 and PtdIns4Kh, and
coprecipitation studies demonstrate that the EGF receptor is
associated with PtdIns4Kh and PLCg1 [19,21,37–39]. Acti-
vation of these enzymes resulting in phosphoinositide turn-
over results in the generation of the intracellular signalling
molecules, diacylglycerol and inositol trisphosphate. These
second messengers initiate many activities associated with
increased cell proliferation and growth, consistent with the
increased epithelial cell proliferation observed in PKD
[40,41].
Binding of growth factors to their receptors results in
autophosphorylation of the receptor itself and other proteins.
This autophosphorylation creates high affinity binding sites
for SH2 domain-containing proteins including the receptor,
resulting in its dimerization and recruitment of SH2 domain-
containing proteins such as PLCg1. Hence, upon stimula-
tion, PLCg1 translocates from the cytosol to the membrane
of the cell, where it is activated and acts on its substrate,
PtdIns-4,5-P2 [42,43]. With activation, therefore, one would
expect increased levels of PLCg1 associated with the mem-
brane fraction and a concomitant decrease in this protein in
the cytosol. In our studies, however, we observed an
increase in the levels of PLCg1 in both the cytosolic and
membrane-associated fractions, suggesting an overall
increase in the expression of this protein. Overexpression
of PLCg1 protein occurs in various carcinomas including
human breast and colorectal cancer tissues [44,45] and in
hyperproliferative epidermal diseases [46]. The regulation
of PLCg1 expression has not been well characterized, but the
activation of the vitamin D-responsive element has been
shown to increase PLCg1 expression [47]. Although little is
known also regarding the control of PtdIns4K expression,
elevated PtdIns4K activity is associated with cell prolifer-
ation in tumours, newborn and regenerating liver, thymus,
bone marrow, spleen and testis [48]. Our study demonstrates
that the levels of PtdIns4K and PLCg1 are elevated in PKD
kidneys of two animal models. However, the mechanism by
which the expression of these proteins is altered in diseased
kidneys, whether increased expression is found in other
hyperproliferative renal disorders and how this is regulated
remains to be determined.
Although PtdIns-4-P is the predominant isomer of
PtdInsP in the kidney, low levels of PtdIns-3-P are also
found in the kidney, with the level of isotopically labelled
PtdIns-3-P being less than 2% of total PtdInsP [3,4]. In one
study, the relative amount of PtdIns-3-P was not different in
normal compared to pcy mouse kidneys, although the level
of this isomer did correlate with increasing kidney size in
cystic kidneys [4]. In the current study, the levels of
PtdIns3K were not different in pcy mouse kidneys compared
to controls, consistent with the findings on the levels of this
F.P. Cuozzo et al. / Biochimica et Biophysica Acta 1587 (2002) 99–106104
specific phosphoinositide isomer. The fact that the level
of PtdIns3K was not elevated suggests that the higher
PtdIns4Kh and PLCg1 levels are not simply part of a ge-
neralized increase in tyrosine kinase activity and phosphoi-
nositide turnover, but represent specific alterations in these
diseased kidneys which remain to be elucidated.
Our previous studies indicated that hepatic phosphoino-
sitide levels were not altered in the pcy mice [3]. In contrast
to human PKD, in which hepatic cysts commonly occur, the
livers in these mice do not contain cysts, and the levels of
PtdIns4Kh and PLCg1 were not elevated in this tissue,
suggesting that the phosphoinositide alterations seen in the
kidney are specific for the diseased tissue. Our data do not
explain why the levels of these enzymes are lower in the
liver fractions of 180-day-old pcy mice. However, reduced
levels of these enzymes is consistent with the reduced
growth of the liver and lower body weights in these animals
[3].
The greater changes in enzyme alterations in male
Han:SPRD-cy rats is likely a reflection of the greater
severity of disease in males in this model of PKD. The
reason for the earlier appearance of these abnormalities in
the female compared to male pcy mouse, however, is not
readily apparent. Initial reports of this model with the pcy
mutation on the DBA/2J background reported that cystic
females developed severe uremia and died sooner than their
male counterparts. However, we have observed that disease
progression in male and female pcy mice with the pcy
mutation on the CD1 background occurs at similar rates,
and on some diets disease progression is slower in females
than in males [14,49].
The overexpression of these enzymes in two distinct
models of PKD demonstrates the importance of the phos-
phoinositide signalling pathway in this disorder. It is clear
that inhibition of EGF signalling can reduce disease pro-
gression [34–36]. Strategies which alter enzymes in growth
factor-mediated phosphoinositide signalling pathways may
offer opportunities for therapeutic interventions in this
disorder and further our understanding of molecular events
which regulate the expression of these proteins.
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